Vasile Musteata
State University of Medicine and Pharmacy â??N. Testemitanuâ?, Institute of Oncology, Republic of Moldova
Posters-Accepted Abstracts: J Cancer Sci Ther
This descriptive and clinico-analytic study comprized 125 patients with chronic myelogenous leukemia (CML), who had been followed up at the Institute of Oncology between 2002 â?? 2013. The diagnosis was established in chronic phase in 113 (90,4 ?± 2,32%) cases, in accelerated and acute phases in 12 (9,6 ?± 2,02%). The patient age ranged between 19 â?? 81 years, with the most frequently affected group of 40 â?? 49 years (27.4 ?± 4.89%). The median age was 46.1 ?± 2.13 years old. The median male/ female ratio was 1.4:1, with the age-adjusted limits of 1.1 â?? 1.8:1. In spite of the slow incidence increase (2010 â?? 0,81%ooo, 2014 â?? 0.83%ooo), the prevalence of CML grew progressively (2005 â?? 2.11%ooo, 2014 â?? 4.16%ooo). The northern (27 patients / 32.1 ?± 5.10%) and central (25 patients / 29.8 ?± 4.99%) regions population proved to be mainly affected by CML. 50 (59.6 ?± 4.99%) patients were exposed to insolation during professional activities and daily life (correlation coefficient 0.479). The discriminant analysis of the late diagnosis factors revealed the higher coefficient of canonical correlation for asymptomatic /oligosymptomatic onset of the disease (0.548). 81 (64.8%) patients were approved for GIPAP, and 4 (4.0%) â?? for NOAT Program. The enrollment in GIPAP and NOAT Program, with imatinib and nilotinib therapies significantly improved (p<0.01) the performance status in 90.5% of patients (ECOG-WHO score 0 â?? 1, P?±ES% = 0.25 ?± 0.06), as compared to the non-TKIs chemotherapy. The overall 3-year survival in TKIs -treated patients (66.0%) outstripped (p<0.05) that one obtained under the non-TKIs chemotherapy (44.5%).
Email: vasile.musteata@usmf.md
Cancer Science & Therapy received 3968 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 